Downregulation of miR-342 is associated with tamoxifen resistant breast tumors

BACKGROUND: Tumor resistance to the selective estrogen receptor modulator tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress HER2. We have recently demonstrated that the clinically important isoform of HER2, HERΔ16, promotes therapeutically refracto...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Cittelly, Diana M, Das, Partha M, Spoelstra, Nicole S, Edgerton, Susan M, Richer, Jennifer K, Thor, Ann D, Jones, Frank E
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2010
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3024251/
https://ncbi.nlm.nih.gov/pubmed/21172025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-9-317
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares